FANSIDAR
LOE ApproachingNDAORALTABLETPriority Review
Approved
Oct 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FANSIDAR is an oral fixed-dose combination tablet approved in 1981 for parasitic infections, primarily malaria. The product is a small molecule indicated for treatment and prophylaxis in regions with drug-resistant malaria. It remains a legacy therapeutic option in Roche's tropical medicine portfolio.
LOE Approaching
Product faces moderate competitive pressure (30/100) and approaching loss of exclusivity, suggesting a mature brand with defensive team focus and limited growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FANSIDAR currently has zero linked job openings, reflecting its mature lifecycle stage and approaching loss of exclusivity. Career opportunities are limited to defensive, maintenance-focused roles in tropical medicine markets rather than growth-driven positions.
Regional Sales ManagerMedical Science Liaison
Worked on FANSIDAR at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.